Genprex, Inc. received a Nasdaq delisting notice on August 19, 2025, due to a stockholders' equity below the required $2.5 million (reported at $1.39 million) and failure to meet the $1 minimum bid price requirement. The company has requested a hearing to present its plan for regaining compliance and to avoid delisting.